APO Research
Talk to an analyst

APO RESEARCH · REPORT

SARS-CoV-2 IgG (RBD) ELISA

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global SARS-CoV-2 IgG (RBD) ELISA Market Analysis and Forecast 2026-2032

30 December 2025199 pages

Choose your research edition.

Industry ResearchSARS-CoV-2 IgG (RBD) ELISA Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal SARS-CoV-2 IgG (RBD) ELISA Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal SARS-CoV-2 IgG (RBD) ELISA Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal SARS-CoV-2 IgG (RBD) ELISA Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal SARS-CoV-2 IgG (RBD) ELISA Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global SARS-CoV-2 IgG (RBD) ELISA market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for SARS-CoV-2 IgG (RBD) ELISA is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for SARS-CoV-2 IgG (RBD) ELISA is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for SARS-CoV-2 IgG (RBD) ELISA is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for SARS-CoV-2 IgG (RBD) ELISA is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of SARS-CoV-2 IgG (RBD) ELISA include ALPCO, BD Biosciences, BioMérieux, Bio-Rad Laboratories, Enzo Life Sciences, LG, LOEWE Biochemica, Ortho Clinical Diagnostics and R&D Systems, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for SARS-CoV-2 IgG (RBD) ELISA, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of SARS-CoV-2 IgG (RBD) ELISA, also provides the revenue of main regions and countries. Of the upcoming market potential for SARS-CoV-2 IgG (RBD) ELISA, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the SARS-CoV-2 IgG (RBD) ELISA revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global SARS-CoV-2 IgG (RBD) ELISA market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for SARS-CoV-2 IgG (RBD) ELISA revenue, projected growth trends, production technology, application and end-user industry.

SARS-CoV-2 IgG (RBD) ELISA Segment by Company

ALPCO

BD Biosciences

BioMérieux

Bio-Rad Laboratories

Enzo Life Sciences

LG

LOEWE Biochemica

Ortho Clinical Diagnostics

R&D Systems

Shenzhen YHLO Biotech

ZEUS Scientific

Thermo Fisher Scientific

SARS-CoV-2 IgG (RBD) ELISA Segment by Type

ELISA Sets

ELISA Kits

SARS-CoV-2 IgG (RBD) ELISA Segment by Application

Hospital

Clinic

Disease control and prevention system

SARS-CoV-2 IgG (RBD) ELISA Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global SARS-CoV-2 IgG (RBD) ELISA market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of SARS-CoV-2 IgG (RBD) ELISA and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of SARS-CoV-2 IgG (RBD) ELISA.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of SARS-CoV-2 IgG (RBD) ELISA in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of SARS-CoV-2 IgG (RBD) ELISA company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, SARS-CoV-2 IgG (RBD) ELISA revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global SARS-CoV-2 IgG (RBD) ELISA Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. ELISA Sets Major Player Table 3. ELISA Kits Major Player Table 4. Global SARS-CoV-2 IgG (RBD) ELISA Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Clinic Major Player Table 7. Disease control and prevention system Major Player Table 8. SARS-CoV-2 IgG (RBD) ELISA Industry Trends Table 9. SARS-CoV-2 IgG (RBD) ELISA Industry Drivers Table 10. SARS-CoV-2 IgG (RBD) ELISA Industry Opportunities and Challenges Table 11. SARS-CoV-2 IgG (RBD) ELISA Industry Restraints Table 12. Global SARS-CoV-2 IgG (RBD) ELISA Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global SARS-CoV-2 IgG (RBD) ELISA Market Size by Region (2021-2026) & (US$ Million) Table 14. Global SARS-CoV-2 IgG (RBD) ELISA Market Share by Region (2021-2026) Table 15. Global SARS-CoV-2 IgG (RBD) ELISA Market Size by Region (2027-2032) & (US$ Million) Table 16. Global SARS-CoV-2 IgG (RBD) ELISA Market Share by Region (2027-2032) Table 17. Global SARS-CoV-2 IgG (RBD) ELISA Revenue by Players (US$ Million) & (2021-2026) Table 18. Global SARS-CoV-2 IgG (RBD) ELISA Revenue Market Share by Players (2021-2026) Table 19. Global SARS-CoV-2 IgG (RBD) ELISA Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global SARS-CoV-2 IgG (RBD) ELISA Key Players Headquarters & Area Served Table 21. Global SARS-CoV-2 IgG (RBD) ELISA Players, Product Type & Application Table 22. Global SARS-CoV-2 IgG (RBD) ELISA Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global SARS-CoV-2 IgG (RBD) ELISA by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global SARS-CoV-2 IgG (RBD) ELISA Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2021-2026) & (US$ Million) Table 27. Global SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2027-2032) & (US$ Million) Table 28. Global SARS-CoV-2 IgG (RBD) ELISA Revenue Market Share by Type (2021-2026) Table 29. Global SARS-CoV-2 IgG (RBD) ELISA Revenue Market Share by Type (2027-2032) Table 30. Global SARS-CoV-2 IgG (RBD) ELISA Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2021-2026) & (US$ Million) Table 32. Global SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2027-2032) & (US$ Million) Table 33. Global SARS-CoV-2 IgG (RBD) ELISA Revenue Market Share by Application (2021-2026) Table 34. Global SARS-CoV-2 IgG (RBD) ELISA Revenue Market Share by Application (2027-2032) Table 35. ALPCO Company Information Table 36. ALPCO Business Overview Table 37. ALPCO SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. ALPCO SARS-CoV-2 IgG (RBD) ELISA Product Portfolio Table 39. ALPCO Recent Development Table 40. BD Biosciences Company Information Table 41. BD Biosciences Business Overview Table 42. BD Biosciences SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. BD Biosciences SARS-CoV-2 IgG (RBD) ELISA Product Portfolio Table 44. BD Biosciences Recent Development Table 45. BioMérieux Company Information Table 46. BioMérieux Business Overview Table 47. BioMérieux SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. BioMérieux SARS-CoV-2 IgG (RBD) ELISA Product Portfolio Table 49. BioMérieux Recent Development Table 50. Bio-Rad Laboratories Company Information Table 51. Bio-Rad Laboratories Business Overview Table 52. Bio-Rad Laboratories SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Bio-Rad Laboratories SARS-CoV-2 IgG (RBD) ELISA Product Portfolio Table 54. Bio-Rad Laboratories Recent Development Table 55. Enzo Life Sciences Company Information Table 56. Enzo Life Sciences Business Overview Table 57. Enzo Life Sciences SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Enzo Life Sciences SARS-CoV-2 IgG (RBD) ELISA Product Portfolio Table 59. Enzo Life Sciences Recent Development Table 60. LG Company Information Table 61. LG Business Overview Table 62. LG SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. LG SARS-CoV-2 IgG (RBD) ELISA Product Portfolio Table 64. LG Recent Development Table 65. LOEWE Biochemica Company Information Table 66. LOEWE Biochemica Business Overview Table 67. LOEWE Biochemica SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. LOEWE Biochemica SARS-CoV-2 IgG (RBD) ELISA Product Portfolio Table 69. LOEWE Biochemica Recent Development Table 70. Ortho Clinical Diagnostics Company Information Table 71. Ortho Clinical Diagnostics Business Overview Table 72. Ortho Clinical Diagnostics SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Ortho Clinical Diagnostics SARS-CoV-2 IgG (RBD) ELISA Product Portfolio Table 74. Ortho Clinical Diagnostics Recent Development Table 75. R&D Systems Company Information Table 76. R&D Systems Business Overview Table 77. R&D Systems SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. R&D Systems SARS-CoV-2 IgG (RBD) ELISA Product Portfolio Table 79. R&D Systems Recent Development Table 80. Shenzhen YHLO Biotech Company Information Table 81. Shenzhen YHLO Biotech Business Overview Table 82. Shenzhen YHLO Biotech SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Shenzhen YHLO Biotech SARS-CoV-2 IgG (RBD) ELISA Product Portfolio Table 84. Shenzhen YHLO Biotech Recent Development Table 85. ZEUS Scientific Company Information Table 86. ZEUS Scientific Business Overview Table 87. ZEUS Scientific SARS-CoV-2 IgG (RBD) ELISA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. ZEUS Scientific SARS-CoV-2 IgG (RBD) ELISA Product Portfolio Table 89. ZEUS Scientific Recent Development Table 90. Thermo Fisher Scientific Company Information Table 91. Thermo Fisher Scientific Business Overview Table 92. Thermo Fisher Scientific SARS-CoV-2 IgG (RBD) ELISA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Thermo Fisher Scientific SARS-CoV-2 IgG (RBD) ELISA Product Portfolio Table 94. Thermo Fisher Scientific Recent Development Table 95. North America SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2021-2026) & (US$ Million) Table 96. North America SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2027-2032) & (US$ Million) Table 97. North America SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2021-2026) & (US$ Million) Table 98. North America SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2027-2032) & (US$ Million) Table 99. North America SARS-CoV-2 IgG (RBD) ELISA Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 100. North America SARS-CoV-2 IgG (RBD) ELISA Revenue by Country (2021-2026) & (US$ Million) Table 101. North America SARS-CoV-2 IgG (RBD) ELISA Revenue by Country (US$ Million) & (2027-2032) Table 102. Europe SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2021-2026) & (US$ Million) Table 103. Europe SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2027-2032) & (US$ Million) Table 104. Europe SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2021-2026) & (US$ Million) Table 105. Europe SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2027-2032) & (US$ Million) Table 106. Europe SARS-CoV-2 IgG (RBD) ELISA Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. Europe SARS-CoV-2 IgG (RBD) ELISA Revenue by Country (2021-2026) & (US$ Million) Table 108. Europe SARS-CoV-2 IgG (RBD) ELISA Revenue by Country (US$ Million) & (2027-2032) Table 109. China SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2021-2026) & (US$ Million) Table 110. China SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2027-2032) & (US$ Million) Table 111. China SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2021-2026) & (US$ Million) Table 112. China SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2027-2032) & (US$ Million) Table 113. Asia SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2021-2026) & (US$ Million) Table 114. Asia SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2027-2032) & (US$ Million) Table 115. Asia SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2021-2026) & (US$ Million) Table 116. Asia SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2027-2032) & (US$ Million) Table 117. Asia SARS-CoV-2 IgG (RBD) ELISA Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 118. Asia SARS-CoV-2 IgG (RBD) ELISA Revenue by Region (US$ Million) & (2021-2026) Table 119. Asia SARS-CoV-2 IgG (RBD) ELISA Revenue by Region (US$ Million) & (2027-2032) Table 120. SAMEA SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2021-2026) & (US$ Million) Table 121. SAMEA SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2027-2032) & (US$ Million) Table 122. SAMEA SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2021-2026) & (US$ Million) Table 123. SAMEA SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2027-2032) & (US$ Million) Table 124. SAMEA SARS-CoV-2 IgG (RBD) ELISA Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 125. SAMEA SARS-CoV-2 IgG (RBD) ELISA Revenue by Country (2021-2026) & (US$ Million) Table 126. SAMEA SARS-CoV-2 IgG (RBD) ELISA Revenue by Country (US$ Million) & (2027-2032) Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. SARS-CoV-2 IgG (RBD) ELISA Image Figure 2. Global SARS-CoV-2 IgG (RBD) ELISA Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global SARS-CoV-2 IgG (RBD) ELISA Market Size Share 2021 VS 2025 VS 2032 Figure 4. ELISA Sets Image Figure 5. ELISA Kits Image Figure 6. Global SARS-CoV-2 IgG (RBD) ELISA Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global SARS-CoV-2 IgG (RBD) ELISA Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Clinic Image Figure 10. Disease control and prevention system Image Figure 11. Global SARS-CoV-2 IgG (RBD) ELISA Market Size (US$ Million) & (2021-2032) Figure 12. Global SARS-CoV-2 IgG (RBD) ELISA Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global SARS-CoV-2 IgG (RBD) ELISA Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global SARS-CoV-2 IgG (RBD) ELISA Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global SARS-CoV-2 IgG (RBD) ELISA Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global SARS-CoV-2 IgG (RBD) ELISA Revenue Market Share by Type (2021-2032) Figure 19. Global SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global SARS-CoV-2 IgG (RBD) ELISA Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global SARS-CoV-2 IgG (RBD) ELISA Revenue Market Share by Application (2021-2032) Figure 22. North America SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America SARS-CoV-2 IgG (RBD) ELISA Revenue Share by Type (2021-2032) Figure 24. North America SARS-CoV-2 IgG (RBD) ELISA Revenue Share by Application (2021-2032) Figure 25. North America SARS-CoV-2 IgG (RBD) ELISA Revenue Share by Country (2021-2032) Figure 26. United States SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe SARS-CoV-2 IgG (RBD) ELISA Revenue Share by Type (2021-2032) Figure 31. Europe SARS-CoV-2 IgG (RBD) ELISA Revenue Share by Application (2021-2032) Figure 32. Europe SARS-CoV-2 IgG (RBD) ELISA Revenue Share by Country (2021-2032) Figure 33. Germany SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China SARS-CoV-2 IgG (RBD) ELISA Revenue Share by Type (2021-2032) Figure 43. China SARS-CoV-2 IgG (RBD) ELISA Revenue Share by Application (2021-2032) Figure 44. Asia SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia SARS-CoV-2 IgG (RBD) ELISA Revenue Share by Type (2021-2032) Figure 46. Asia SARS-CoV-2 IgG (RBD) ELISA Revenue Share by Application (2021-2032) Figure 47. Asia SARS-CoV-2 IgG (RBD) ELISA Revenue Share by Region (2021-2032) Figure 48. Japan SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA SARS-CoV-2 IgG (RBD) ELISA Revenue Share by Type (2021-2032) Figure 56. SAMEA SARS-CoV-2 IgG (RBD) ELISA Revenue Share by Application (2021-2032) Figure 57. SAMEA SARS-CoV-2 IgG (RBD) ELISA Revenue Share by Country (2021-2032) Figure 58. Brazil SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt SARS-CoV-2 IgG (RBD) ELISA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • ELISA Sets
  • ELISA Kits
Applications
  • Hospital
  • Clinic
  • Disease control and prevention system
Companies covered
  • ALPCO
  • BD Biosciences
  • BioMérieux
  • Bio-Rad Laboratories
  • Enzo Life Sciences
  • LG
  • LOEWE Biochemica
  • Ortho Clinical Diagnostics
  • R&D Systems
  • Shenzhen YHLO Biotech
  • ZEUS Scientific
  • Thermo Fisher Scientific

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 SARS-CoV-2 IgG (RBD) ELISA Market by Type
  3. 1.2.1 Global SARS-CoV-2 IgG (RBD) ELISA Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 ELISA Sets
  5. 1.2.3 ELISA Kits
  6. 1.3 SARS-CoV-2 IgG (RBD) ELISA Market by Application
  7. 1.3.1 Global SARS-CoV-2 IgG (RBD) ELISA Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Clinic
  10. 1.3.4 Disease control and prevention system
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 SARS-CoV-2 IgG (RBD) ELISA Market Dynamics
  1. 2.1 SARS-CoV-2 IgG (RBD) ELISA Industry Trends
  2. 2.2 SARS-CoV-2 IgG (RBD) ELISA Industry Drivers
  3. 2.3 SARS-CoV-2 IgG (RBD) ELISA Industry Opportunities and Challenges
  4. 2.4 SARS-CoV-2 IgG (RBD) ELISA Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global SARS-CoV-2 IgG (RBD) ELISA Market Perspective (2021-2032)
  2. 3.2 Global SARS-CoV-2 IgG (RBD) ELISA Growth Trends by Region
  3. 3.2.1 Global SARS-CoV-2 IgG (RBD) ELISA Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global SARS-CoV-2 IgG (RBD) ELISA Market Size by Region (2021-2026)
  5. 3.2.3 Global SARS-CoV-2 IgG (RBD) ELISA Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global SARS-CoV-2 IgG (RBD) ELISA Revenue by Players
  2. 4.1.1 Global SARS-CoV-2 IgG (RBD) ELISA Revenue by Players (2021-2026)
  3. 4.1.2 Global SARS-CoV-2 IgG (RBD) ELISA Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global SARS-CoV-2 IgG (RBD) ELISA Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global SARS-CoV-2 IgG (RBD) ELISA Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global SARS-CoV-2 IgG (RBD) ELISA Key Players Headquarters & Area Served
  7. 4.4 Global SARS-CoV-2 IgG (RBD) ELISA Players, Product Type & Application
  8. 4.5 Global SARS-CoV-2 IgG (RBD) ELISA Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global SARS-CoV-2 IgG (RBD) ELISA Market CR5 and HHI
  11. 4.6.3 2025 SARS-CoV-2 IgG (RBD) ELISA Tier 1, Tier 2, and Tier 3
5 SARS-CoV-2 IgG (RBD) ELISA Market Size by Type
  1. 5.1 Global SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2021-2032)
  3. 5.3 Global SARS-CoV-2 IgG (RBD) ELISA Revenue Market Share by Type (2021-2032)
6 SARS-CoV-2 IgG (RBD) ELISA Market Size by Application
  1. 6.1 Global SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2021-2032)
  3. 6.3 Global SARS-CoV-2 IgG (RBD) ELISA Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 ALPCO
  2. 7.1.1 ALPCO Company Information
  3. 7.1.2 ALPCO Business Overview
  4. 7.1.3 ALPCO SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2021-2026)
  5. 7.1.4 ALPCO SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
  6. 7.1.5 ALPCO Recent Developments
  7. 7.2 BD Biosciences
  8. 7.2.1 BD Biosciences Company Information
  9. 7.2.2 BD Biosciences Business Overview
  10. 7.2.3 BD Biosciences SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2021-2026)
  11. 7.2.4 BD Biosciences SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
  12. 7.2.5 BD Biosciences Recent Developments
  13. 7.3 BioMérieux
  14. 7.3.1 BioMérieux Company Information
  15. 7.3.2 BioMérieux Business Overview
  16. 7.3.3 BioMérieux SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2021-2026)
  17. 7.3.4 BioMérieux SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
  18. 7.3.5 BioMérieux Recent Developments
  19. 7.4 Bio-Rad Laboratories
  20. 7.4.1 Bio-Rad Laboratories Company Information
  21. 7.4.2 Bio-Rad Laboratories Business Overview
  22. 7.4.3 Bio-Rad Laboratories SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Bio-Rad Laboratories SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
  24. 7.4.5 Bio-Rad Laboratories Recent Developments
  25. 7.5 Enzo Life Sciences
  26. 7.5.1 Enzo Life Sciences Company Information
  27. 7.5.2 Enzo Life Sciences Business Overview
  28. 7.5.3 Enzo Life Sciences SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Enzo Life Sciences SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
  30. 7.5.5 Enzo Life Sciences Recent Developments
  31. 7.6 LG
  32. 7.6.1 LG Company Information
  33. 7.6.2 LG Business Overview
  34. 7.6.3 LG SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2021-2026)
  35. 7.6.4 LG SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
  36. 7.6.5 LG Recent Developments
  37. 7.7 LOEWE Biochemica
  38. 7.7.1 LOEWE Biochemica Company Information
  39. 7.7.2 LOEWE Biochemica Business Overview
  40. 7.7.3 LOEWE Biochemica SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2021-2026)
  41. 7.7.4 LOEWE Biochemica SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
  42. 7.7.5 LOEWE Biochemica Recent Developments
  43. 7.8 Ortho Clinical Diagnostics
  44. 7.8.1 Ortho Clinical Diagnostics Company Information
  45. 7.8.2 Ortho Clinical Diagnostics Business Overview
  46. 7.8.3 Ortho Clinical Diagnostics SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Ortho Clinical Diagnostics SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
  48. 7.8.5 Ortho Clinical Diagnostics Recent Developments
  49. 7.9 R&D Systems
  50. 7.9.1 R&D Systems Company Information
  51. 7.9.2 R&D Systems Business Overview
  52. 7.9.3 R&D Systems SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2021-2026)
  53. 7.9.4 R&D Systems SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
  54. 7.9.5 R&D Systems Recent Developments
  55. 7.10 Shenzhen YHLO Biotech
  56. 7.10.1 Shenzhen YHLO Biotech Company Information
  57. 7.10.2 Shenzhen YHLO Biotech Business Overview
  58. 7.10.3 Shenzhen YHLO Biotech SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Shenzhen YHLO Biotech SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
  60. 7.10.5 Shenzhen YHLO Biotech Recent Developments
  61. 7.11 ZEUS Scientific
  62. 7.11.1 ZEUS Scientific Company Information
  63. 7.11.2 ZEUS Scientific Business Overview
  64. 7.11.3 ZEUS Scientific SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2021-2026)
  65. 7.11.4 ZEUS Scientific SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
  66. 7.11.5 ZEUS Scientific Recent Developments
  67. 7.12 Thermo Fisher Scientific
  68. 7.12.1 Thermo Fisher Scientific Company Information
  69. 7.12.2 Thermo Fisher Scientific Business Overview
  70. 7.12.3 Thermo Fisher Scientific SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Thermo Fisher Scientific SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
  72. 7.12.5 Thermo Fisher Scientific Recent Developments
8 North America
  1. 8.1 North America SARS-CoV-2 IgG (RBD) ELISA Revenue (2021-2032)
  2. 8.2 North America SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2021-2032)
  3. 8.2.1 North America SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2021-2026)
  4. 8.2.2 North America SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2027-2032)
  5. 8.3 North America SARS-CoV-2 IgG (RBD) ELISA Revenue Share by Type (2021-2032)
  6. 8.4 North America SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2021-2032)
  7. 8.4.1 North America SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2021-2026)
  8. 8.4.2 North America SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2027-2032)
  9. 8.5 North America SARS-CoV-2 IgG (RBD) ELISA Revenue Share by Application (2021-2032)
  10. 8.6 North America SARS-CoV-2 IgG (RBD) ELISA Revenue by Country
  11. 8.6.1 North America SARS-CoV-2 IgG (RBD) ELISA Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America SARS-CoV-2 IgG (RBD) ELISA Revenue by Country (2021-2026)
  13. 8.6.3 North America SARS-CoV-2 IgG (RBD) ELISA Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe SARS-CoV-2 IgG (RBD) ELISA Revenue (2021-2032)
  2. 9.2 Europe SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2021-2032)
  3. 9.2.1 Europe SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2021-2026)
  4. 9.2.2 Europe SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2027-2032)
  5. 9.3 Europe SARS-CoV-2 IgG (RBD) ELISA Revenue Share by Type (2021-2032)
  6. 9.4 Europe SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2021-2032)
  7. 9.4.1 Europe SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2021-2026)
  8. 9.4.2 Europe SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2027-2032)
  9. 9.5 Europe SARS-CoV-2 IgG (RBD) ELISA Revenue Share by Application (2021-2032)
  10. 9.6 Europe SARS-CoV-2 IgG (RBD) ELISA Revenue by Country
  11. 9.6.1 Europe SARS-CoV-2 IgG (RBD) ELISA Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe SARS-CoV-2 IgG (RBD) ELISA Revenue by Country (2021-2026)
  13. 9.6.3 Europe SARS-CoV-2 IgG (RBD) ELISA Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China SARS-CoV-2 IgG (RBD) ELISA Revenue (2021-2032)
  2. 10.2 China SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2021-2032)
  3. 10.2.1 China SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2021-2026)
  4. 10.2.2 China SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2027-2032)
  5. 10.3 China SARS-CoV-2 IgG (RBD) ELISA Revenue Share by Type (2021-2032)
  6. 10.4 China SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2021-2032)
  7. 10.4.1 China SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2021-2026)
  8. 10.4.2 China SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2027-2032)
  9. 10.5 China SARS-CoV-2 IgG (RBD) ELISA Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia SARS-CoV-2 IgG (RBD) ELISA Revenue (2021-2032)
  2. 11.2 Asia SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2021-2032)
  3. 11.2.1 Asia SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2021-2026)
  4. 11.2.2 Asia SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2027-2032)
  5. 11.3 Asia SARS-CoV-2 IgG (RBD) ELISA Revenue Share by Type (2021-2032)
  6. 11.4 Asia SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2021-2032)
  7. 11.4.1 Asia SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2021-2026)
  8. 11.4.2 Asia SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2027-2032)
  9. 11.5 Asia SARS-CoV-2 IgG (RBD) ELISA Revenue Share by Application (2021-2032)
  10. 11.6 Asia SARS-CoV-2 IgG (RBD) ELISA Revenue by Country
  11. 11.6.1 Asia SARS-CoV-2 IgG (RBD) ELISA Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia SARS-CoV-2 IgG (RBD) ELISA Revenue by Country (2021-2026)
  13. 11.6.3 Asia SARS-CoV-2 IgG (RBD) ELISA Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA SARS-CoV-2 IgG (RBD) ELISA Revenue (2021-2032)
  2. 12.2 SAMEA SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA SARS-CoV-2 IgG (RBD) ELISA Revenue by Type (2027-2032)
  5. 12.3 SAMEA SARS-CoV-2 IgG (RBD) ELISA Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA SARS-CoV-2 IgG (RBD) ELISA Revenue by Application (2027-2032)
  9. 12.5 SAMEA SARS-CoV-2 IgG (RBD) ELISA Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA SARS-CoV-2 IgG (RBD) ELISA Revenue by Country
  11. 12.6.1 SAMEA SARS-CoV-2 IgG (RBD) ELISA Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA SARS-CoV-2 IgG (RBD) ELISA Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA SARS-CoV-2 IgG (RBD) ELISA Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst